Начало › Множествен миелом › Флорида › Miami
Клинични проучвания за Множествен миелом в Miami, FL
21 проучвания за Множествен миелом търсят участници в обекти в и около Miami (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Набиране на участнициФаза 1/2
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набиране на участнициФаза 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- и още 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Набиране на участнициФаза 2
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Набиране на участнициФаза 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Набиране на участнициФаза 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- и още 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Набиране на участнициФаза 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Набиране на участнициФаза 2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Набиране на участнициФаза 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набиране на участнициФаза 1/2
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Набиране на участнициФаза 1
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Набиране на участнициФаза 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Набиране на участници
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Набиране на участнициНаблюдателно проучване
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набиране на участнициФаза 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 2
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Набиране на участнициФаза 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Набиране на участнициФаза 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Проучвания за Множествен миелом в други градове
- New York City, NY60 проучвания
- Boston, MA42 проучвания
- Atlanta, GA41 проучвания
- Houston, TX38 проучвания
- Durham, NC37 проучвания
- Nashville, TN32 проучвания
- Denver, CO27 проучвания
- Rochester, MN24 проучвания
- St. Louis, MO24 проучвания
- Columbus, OH24 проучвания
- Baldwin Park, CA23 проучвания
- Chicago, IL22 проучвания
Други проучвания в Miami
- Рак на гърдата42 проучвания
- Рак (всички видове)36 проучвания
- Рак на белия дроб с недребноклетъчен тип31 проучвания
- Рак на простатата27 проучвания
- Затлъстяване27 проучвания
- Остра миелоидна левкемия24 проучвания
- Метастатичен рак24 проучвания
- Рак на яйчниците23 проучвания
- Наднормено тегло23 проучвания
- Язвенен колит21 проучвания
- Болест на Алцхаймер20 проучвания
- Рак на белия дроб20 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.